BTLA expression contributes to septic morbidity and mortality by inducing innate inflammatory cell dysfunction
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
BTLA expression contributes to increased septic morbidity, mortality, and decreased innate cell activity in mice, while BTLA+ blood monocyte levels increase in septic ICU patients. A proper innate inflammatory response is essential for prevention of the systemic inflammation associated with sepsis. BTLA is an immune-regulatory receptor demonstrated to be expressed not only on adaptive immune populations and have potent inhibitory effects on CD4+ T cells but is also expressed on innate cell populations (CD11c+ and CD11b+ cells) and has been shown to diminish pathogen clearance following bacterial and parasite infection. The role of BTLA in sepsis and the mechanisms by which BTLA alters pathogen clearance, however, have not been addressed clearly. Here, we show that following acute experimental sepsis induction in mice (CLP), the number of infiltrating BTLA- and HVEM (the ligand for BTLA)-expressing macrophages, inflammatory monocytes, mature and immature DCs, and neutrophils increased in the peritoneum compared with sham surgery, suggesting that a high level of HVEM:BTLA interactions occurs between these cells at the site of septic insult. Given this, we evaluated BTLA−/− mice, 24 h post-CLP, and observed a marked increase in the degree of activation on these cell populations, as well as a reduction in peritoneal bacterial burden and IL-10 induction, and most importantly, BTLA−/− mice exhibited a higher rate of survival and protection from organ injury when compared with WT mice. Such changes were not restricted to experimental mice, as circulating BTLA+ and HVEM+ monocytes and HVEM+ granulocytes were increased in septic ICU patients, supporting a role for BTLA and/or HVEM as potential, novel diagnostic markers of innate immune response/status and as therapeutic targets of sepsis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction
Trautmann, L., Janbazian, L., Chomont, N., Said, E. A., Gimmig, S., Bessette, B., Boulassel, M.-R., Delwart, E., Sepulveda, H., Balderas, R. S., et al. (2006) · Nature Medicine · doi:10.1038/nm1482 · Cited by 1,565 · cited 1×
“Research investigating the effect of coinhibitory receptors, including PD-1, CTLA-4, and BTLA, has implicated these receptors as being important for contributing to the progression of a number of disease states and inflammatory conditions, including cancer [23], HIV [24, 25], IBD, graft-versus-host disease [26–28], an…”
BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1
Watanabe, N., Gavrieli, M., Sedy, J. R., Yang, J., Fallarino, F., Loftin, S. K., Hurchla, M. A., Zimmerman, N., Sim, J., Zang, X., et al. (2003) · Nature Immunology · doi:10.1038/ni944 · Cited by 883 · cited 1×
“BTLA has been shown to inhibit CD4 T cell proliferation, polarization into Th1 cells, as well as inducing CD4 T cell apoptosis [11, 34].”
PD-1 signaling in primary T cells
Riley, J. L. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00767.x · Cited by 778 · cited 1×
“Coinhibitory receptors, such as PD-1, CTLA-4, and more recently, BTLA, are Ig-type/ITIM-containing receptors that have been demonstrated to inhibit activation and proliferation of T cells [8].”
Regulation of inflammation, autoimmunity, and infection immunity by HVEM-BTLA signaling
Shui, J.-W., Steinberg, M. W., & Kronenberg, M. (2010) · Journal of Leukocyte Biology · doi:10.1189/jlb.0910528 · Cited by 109
B and T Lymphocyte Attenuator Tempers Early Infection Immunity
Sun, Y., Brown, N. K., Ruddy, M. J., Miller, M. L., Lee, Y., Wang, Y., Murphy, K. M., Pfeffer, K., Chen, L., Kaye, J., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0801866 · Cited by 51 · cited 3×
“monocytogenes, an intracellular-bacterial pathogen, and on the intracellular protozoan parasite, Plasmodium, which causes malaria, suggesting a role for BTLA in inhibiting innate phagocytic cell action [12, 13].”
Research works printed but not linked: 33
- Levy, 2003, 2001 SCCM/ESICM/ACCP/ATS/SIS International sepsis definitions conference, Crit. Care Med., 31, 1250, 10.1097/01.CCM.0000050454.01978.3B · DOI · Paper page
- Bone, 1996, Sir Isaac Newton, sepsis, SIRS, and CARS, Crit. Care Med., 24, 1125, 10.1097/00003246-199607000-00010 · DOI · Paper page
- Ayala, 1994, Polymicrobial sepsis but not low-dose endotoxin infusion causes decreased splenocyte IL-2/IFN-gamma release while increasing IL-4/IL-10 production, J. Surg. Res., 56, 579, 10.1006/jsre.1994.1092 · DOI
- Huang, 2007, Changes in dendritic cell function in the immune response to sepsis. Cell- & tissue-based therapy, Expert Opin. Biol. Ther., 7, 929, 10.1517/14712598.7.7.929 · DOI
- Ayala, 1992, Polymicrobial sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (interleukins-1 and -6 and tumor necrosis factor), Circ. Shock, 36, 191
- Ellaban, 2004, Selective macrophage suppression during sepsis, Cell. Immunol., 231, 103, 10.1016/j.cellimm.2004.12.010 · DOI
- Newton, 2004, Sepsis-induced changes in macrophage co-stimulatory molecule expression: CD86 as a regulator of anti-inflammatory IL-10 response, Surg. Infect. (Larchmt.), 5, 375, 10.1089/sur.2004.5.375 · DOI
- Del Rio, 2010, HVEM/LIGHT/BTLA/CD160 cosignaling pathways as targets for immune regulation, J. Leukoc. Biol., 87, 223, 10.1189/jlb.0809590 · DOI · Paper page
- Paulos, 2010, Putting the brakes on BTLA in T cell-mediated cancer immunotherapy, J. Clin. Invest., 120, 76, 10.1172/JCI41811 · DOI
- Adler, 2011, B and T Lymphocyte attenuator restricts the protective immune response against experimental malaria, J. Immunol., 187, 5310, 10.4049/jimmunol.1101456 · DOI · Paper page
- Hurchla, 2005, B and T lymphocyte attenuator exhibits structural and expression polymorphisms and is highly Induced in anergic CD4 + T cells, J. Immunol., 174, 3377, 10.4049/jimmunol.174.6.3377 · DOI · Paper page
- Huang, 2009, PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis, Proc. Natl. Acad. Sci. USA., 106, 6303, 10.1073/pnas.0809422106 · DOI · Paper page
- Said, 2010, Programmed death-1-induced interleukin-10 production by monocytes impairs CD4+ T cell activation during HIV infection, Nat. Med., 16, 452, 10.1038/nm.2106 · DOI · Paper page
- Zhang, 2010, PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction, Crit. Care., 14, R220, 10.1186/cc9354 · DOI · Paper page
- Sedy, 2005, B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator, Nat. Immunol., 6, 90, 10.1038/ni1144 · DOI · Paper page
- Ding, 2004, Polymicrobial sepsis induces divergent effects on splenic and peritoneal dendritic cell function in mice, Shock, 22, 137, 10.1097/01.shk.0000131194.80038.3f · DOI
- Ocuin, 2011, Neutrophil IL-10 suppresses peritoneal inflammatory monocytes during polymicrobial sepsis, J. Leukoc. Biol., 89, 423, 10.1189/jlb.0810479 · DOI
- Hu, 2009, The role of hepatic invariant NKT cells in systemic/local inflammation and mortality during polymicrobial septic shock, J. Immunol., 182, 2467, 10.4049/jimmunol.0801463 · DOI
- Astiz, 1996, Monocyte response to bacterial toxins, expression of cell surface receptors, and release of anti-inflammatory cytokines during sepsis, J. Lab. Clin. Med., 128, 594, 10.1016/S0022-2143(96)90132-8 · DOI
- Eggermont, 2011, New drugs in melanoma: It's a whole new world, Eur. J. Cancer., 47, 2150, 10.1016/j.ejca.2011.06.052 · DOI · Paper page
- Khaitan, 2011, Revisiting immune exhaustion during HIV infection, Curr. HIV/AIDS Rep., 8, 4, 10.1007/s11904-010-0066-0 · DOI · Paper page
- Reynoso, 2009, Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade, J. Immunol., 182, 2102, 10.4049/jimmunol.0802769 · DOI · Paper page
- Sakoda, 2011, Dichotomous regulation of GVHD through bidirectional functions of the BTLA-HVEM pathway, Blood, 117, 2506, 10.1182/blood-2010-08-301325 · DOI · Paper page
- Blazar, 2003, Blockade of programmed death-1 engagement accelerates graft-versus-host disease lethality by an IFN-gamma-dependent mechanism, J. Immunol., 171, 1272, 10.4049/jimmunol.171.3.1272 · DOI · Paper page
- Boomer, 2011, Immunosuppression in patients who die of sepsis and multiple organ failure, JAMA, 306, 2594, 10.1001/jama.2011.1829 · DOI · Paper page
- Brahmamdam, 2010, Delayed administration of anti-PD-1 antibody reverses immune dysfunction and improves survival during sepsis, J. Leukoc. Biol., 88, 233, 10.1189/jlb.0110037 · DOI · Paper page
- Inoue, 2011, Dose Dependent Effect of Anti-CTLA-4 on Survival in Sepsis, Shock, 36, 38, 10.1097/SHK.0b013e3182168cce · DOI · Paper page
- Brown, 2010, Role of PD-1 in regulating acute infections, Curr. Opin. Immunol., 22, 397, 10.1016/j.coi.2010.03.007 · DOI · Paper page
- Guignant, 2011, Programmed death-1 levels correlate with increased mortality, nosocomial infection and immune dysfunctions in septic shock patients, Crit. Care, 15, R99, 10.1186/cc10112 · DOI · Paper page
- Pasero, 2009, A role for HVEM, but not lymphotoxin-beta receptor, in LIGHT-induced tumor cell death and chemokine production, Eur. J. Immunol., 39, 2502, 10.1002/eji.200939069 · DOI
- Hol, 2010, The murine IL-8 homologues KC, MIP-2, and LIX are found in endothelial cytoplasmic granules but not in Weibel-Palade bodies, J. Leukoc. Biol., 87, 501, 10.1189/jlb.0809532 · DOI · Paper page
- Nolan, 2009, Differential role for CD80 and CD86 in the regulation of the innate immune response in murine polymicrobial sepsis, PLoS One, 4, e6600, 10.1371/journal.pone.0006600 · DOI
- Laudanski, 2006, Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways, Proc. Natl. Acad. Sci. USA, 103, 15564, 10.1073/pnas.0607028103 · DOI
Cited by
The immunopathology of sepsis and potential therapeutic targets
van der Poll, T., van de Veerdonk, F. L., Scicluna, B. P., & Netea, M. G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2017.36 · Cited by 1,957
Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach
Hotchkiss, R. S., Monneret, G., & Payen, D. (2013) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(13)70001-x · Cited by 1,442
Sepsis: a roadmap for future research
Cohen, J., Vincent, J.-L., Adhikari, N. K. J., Machado, F. R., Angus, D. C., Calandra, T., Jaton, K., Giulieri, S., Delaloye, J., Opal, S., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(15)70112-x · Cited by 992
Schultheiß, C., Paschold, L., Simnica, D., Mohme, M., Willscher, E., von Wenserski, L., Scholz, R., Wieters, I., Dahlke, C., Tolosa, E., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.06.024 · Cited by 333
The changing immune system in sepsis: Is individualized immuno-modulatory therapy the answer?
Boomer, J. S., Green, J. M., & Hotchkiss, R. S. (2014) · Virulence · doi:10.4161/viru.26516 · Cited by 317
Metadata
- Authors
- Shubin, N. J., Chung, C. S., Heffernan, D. S., Irwin, L. R., Monaghan, S. F., & Ayala, A.
- Venue
- Journal of Leukocyte Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-03-29
- Volume
- 92
- Issue
- 3
- Pages
- 593-603
- ISSN
- 0741-5400 (ISSN-L)
- 1938-3673
- OpenAlex
- W2127148037
- Cited by
- 95
- References
- 5
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- Funders
- NIH (GM053209)
- U.S. Department of Education (GAANN-P200A100100)
- Armand D. Versaci Research Scholar in Surgical Sciences Award
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.